{"nctId":"NCT00435019","briefTitle":"Comparison of NPH Insulin and Insulin Detemir in Children and Adolescents With Type 1 Diabetes","startDateStruct":{"date":"2007-02"},"conditions":["Diabetes","Diabetes Mellitus, Type 1"],"count":348,"armGroups":[{"label":"insulin detemir","type":"EXPERIMENTAL","interventionNames":["Drug: insulin detemir","Drug: insulin aspart"]},{"label":"NPH insulin","type":"EXPERIMENTAL","interventionNames":["Drug: insulin NPH","Drug: insulin aspart"]}],"interventions":[{"name":"insulin detemir","otherNames":[]},{"name":"insulin NPH","otherNames":[]},{"name":"insulin aspart","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Insulin detemir naive\n* Type 1 diabetes for at least 12 months\n* HbA1c lesser than or equal to 11.0%\n\nExclusion Criteria:\n\n* Significant concomitant diseases","healthyVolunteers":false,"sex":"ALL","minimumAge":"2 Years","maximumAge":"16 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Glycosylated Haemoglobin A1c (HbA1c)","description":"Glycosylated haemoglobin A1c (HbA1c) measured after 52 weeks of treatment and analysed by central laboratory.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.75","spread":"0.11"},{"groupId":"OG001","value":"8.64","spread":"0.11"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Adverse Events","description":"Number of subjects reporting adverse events during the trial (from week -2 to week 52).\n\nFor details, please refer to the adverse events section.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"132","spread":null},{"groupId":"OG001","value":"135","spread":null}]}]}]},{"type":"SECONDARY","title":"Observed Insulin Antibody Values","description":"Observed insulin antibody values for insulin detemir specific antibodies, insulin aspart specific antibodies and insulin detemir/insulin aspart cross-reacting antibodies.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.23","spread":"1.03"},{"groupId":"OG001","value":"2.95","spread":"1.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.15","spread":"3.30"},{"groupId":"OG001","value":"3.01","spread":"1.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.06","spread":"19.1"},{"groupId":"OG001","value":"27.26","spread":"18.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.70","spread":"15.6"},{"groupId":"OG001","value":"30.19","spread":"17.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.26","spread":"2.32"},{"groupId":"OG001","value":"2.24","spread":"2.99"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.20","spread":"4.35"},{"groupId":"OG001","value":"2.68","spread":"3.60"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":14,"n":177},"commonTop":["Nasopharyngitis","Headache","Pharyngitis","Upper Respiratory Tract Infection","Influenza"]}}}